A.R.T. Advisors’s Corcept Therapeutics CORT Stock Holding History

A.R.T. Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-24,757	Closed	-$300K	–	253
2019 Q4	$300K	Buy	24,757 +5,700	+30%	+$79.3K	0.01%	1027
2019 Q3	$269K	Buy	+19,057	New	+$234K	0.01%	1100
2017 Q4	–	Sell	-129,914	Closed	-$2.51M	–	1417
2017 Q3	$2.51M	Buy	+129,914	New	+$1.94M	0.13%	213
2016 Q3	–	Sell	-13,053	Closed	-$71K	–	739
2016 Q2	$71K	Sell	13,053 -8,500	-39%	-$44.2K	﹤0.01%	1240
2016 Q1	$100K	Sell	21,553 -6,900	-24%	-$26.9K	﹤0.01%	1255
2015 Q4	$141K	Sell	28,453 -91,800	-76%	-$414K	0.01%	1288
2015 Q3	$452K	Buy	120,253 +16,909	+16%	+$85.8K	0.02%	914
2015 Q2	$621K	Buy	103,344 +54,266	+111%	+$333K	0.02%	913
2015 Q1	$274K	Buy	+49,078	New	+$178K	0.01%	1142

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

A.R.T. Advisors's CORT Position: Q1 2020 in Review

A.R.T. Advisors sold out of Corcept Therapeutics (CORT) in Q1 2020, closing a stake of 24,757 shares — an estimated $300K sold.

A.R.T. Advisors first reported a position in CORT in Q1 2015 and held it in 9 quarters. The position peaked at $2.51M in Q3 2017. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

A.R.T. Advisors reported no remaining Corcept Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 24,757 Corcept Therapeutics shares in Q1 2020, an estimated $300K.
A.R.T. Advisors first reported a position in Corcept Therapeutics in Q1 2015 and held it in 9 quarters.
A.R.T. Advisors's Corcept Therapeutics position peaked at $2.51M in Q3 2017.
204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.